

REMARKS/ARGUMENTS

With this amendment, new claims 43-49 are pending. Support for these claims is found throughout the specification, *e.g.*, page 28, line 22 through page 29, line 2; page 30, lines 9-29; page 31, lines 27-29; page 32, lines 2-5; page 33, lines 1-3; page 36-40; page 48, lines 10-12 and Table 2; page 49, line 10 through page 50, line 14; and at SEQ ID NOs: 2, 4, 6, 8, 11, 13, 3, 5, 7, 9, 12, and 14 of the informal sequence listing. Support for fusion proteins is found in the application at, for example, page 40, lines 3-9. These amendments add no new matter.


The first paragraph of the specification is amended to include appropriate priority claims and incorporation by reference of earlier applications. Deletion of the phrase "and claims the benefit" from claims to priority of non-provisional applications is done solely for compliance with language recommendations for claiming benefit of priority issued by the USPTO in 1268 OG 89, March 23, 2003.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,


Beth L. Kelly
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
Attachments
BLK:blk
60165067 v1